{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:47:27Z","timestamp":1774558047126,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["EY022768"],"award-info":[{"award-number":["EY022768"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["EY024236"],"award-info":[{"award-number":["EY024236"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["EY027083"],"award-info":[{"award-number":["EY027083"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["EY026181"],"award-info":[{"award-number":["EY026181"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["P30EY025585"],"award-info":[{"award-number":["P30EY025585"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["EY024236"],"award-info":[{"award-number":["EY024236"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute"},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Challenge Grant"],"award-info":[{"award-number":["Challenge Grant"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Lew Wasserman Award"],"award-info":[{"award-number":["Lew Wasserman Award"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Choroidal neovascularization (CNV) leads to loss of vision in patients with Sorsby Fundus Dystrophy (SFD), an inherited, macular degenerative disorder, caused by mutations in the Tissue Inhibitor of Metalloproteinase-3 (<jats:italic>TIMP3<\/jats:italic>) gene. SFD closely resembles age-related macular degeneration (AMD), which is the leading cause of blindness in the elderly population of the Western hemisphere. Variants in <jats:italic>TIMP3<\/jats:italic> gene have recently been identified in patients with AMD. A majority of patients with AMD also lose vision as a consequence of choroidal neovascularization (CNV). Thus, understanding the molecular mechanisms that contribute to CNV as a consequence of TIMP-3 mutations will provide insight into the pathophysiology in SFD and likely the neovascular component of the more commonly seen AMD. While the role of VEGF in CNV has been studied extensively, it is becoming increasingly clear that other factors likely play a significant role. The objective of this study was to test the hypothesis that basic Fibroblast Growth Factor (bFGF) regulates SFD-related CNV. In this study we demonstrate that mice expressing mutant TIMP3 (<jats:italic>Timp3<\/jats:italic><jats:sup><jats:italic>S179C\/S179C<\/jats:italic><\/jats:sup>) showed reduced MMP inhibitory activity with an increase in MMP2 activity and bFGF levels, as well as accentuated CNV leakage when subjected to laser injury. S179C mutant-TIMP3 in retinal pigment epithelial (RPE) cells showed increased secretion of bFGF and conditioned medium from these cells induced increased angiogenesis in endothelial cells. These studies suggest that S179C-TIMP3 may promote angiogenesis and CNV via a FGFR-1-dependent pathway by increasing bFGF release and activity.<\/jats:p>","DOI":"10.1038\/s41598-019-53433-6","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T11:02:26Z","timestamp":1574420546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism"],"prefix":"10.1038","volume":"9","author":[{"given":"Jian Hua","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Batoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1613-0251","authenticated-orcid":false,"given":"Alyson","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alecia","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Prayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariya","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9094","authenticated-orcid":false,"given":"Bela","family":"Anand-Apte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"53433_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/74651","volume":"6","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6, 389\u2013395 (2000).","journal-title":"Nat Med"},{"key":"53433_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nm0603-653","volume":"9","author":"P Carmeliet","year":"2003","unstructured":"Carmeliet, P. Angiogenesis in health and disease. Nat Med 9, 653\u2013660 (2003).","journal-title":"Nat Med"},{"key":"53433_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0092-8674(00)81810-3","volume":"87","author":"J Folkman","year":"1996","unstructured":"Folkman, J. & D\u2019Amore, P. A. Blood vessel formation: what is its molecular basis? Cell 87, 1153\u20131155 (1996).","journal-title":"Cell"},{"key":"53433_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353\u2013364 (1996).","journal-title":"Cell"},{"key":"53433_CR5","doi-asserted-by":"crossref","unstructured":"Reynolds, L. E. et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8, 27-34 (2002).","DOI":"10.1038\/nm0102-27"},{"key":"53433_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0065-230X(08)60305-X","volume":"59","author":"C Basilico","year":"1992","unstructured":"Basilico, C. & Moscatelli, D. The FGF family of growth factors and oncogenes. Adv Cancer Res 59, 115\u2013165 (1992).","journal-title":"Adv Cancer Res"},{"key":"53433_CR7","first-page":"5117","volume":"60","author":"RA Brekken","year":"2000","unstructured":"Brekken, R. A. et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR\/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60, 5117\u20135124 (2000).","journal-title":"Cancer Res"},{"key":"53433_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1258\/ebm.2009.009191","volume":"235","author":"G Korpanty","year":"2010","unstructured":"Korpanty, G., Smyth, E., Sullivan, L. A., Brekken, R. A. & Carney, D. N. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) 235, 3\u20139, https:\/\/doi.org\/10.1258\/ebm.2009.009191 (2010).","journal-title":"Exp Biol Med (Maywood)"},{"key":"53433_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13, 9\u201322 (1999).","journal-title":"Faseb J"},{"key":"53433_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/PL00001950","volume":"25","author":"Z Poltorak","year":"2000","unstructured":"Poltorak, Z., Cohen, T. & Neufeld, G. The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. Herz 25, 126\u2013129 (2000).","journal-title":"Herz"},{"key":"53433_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4161\/mabs.2.2.11360","volume":"2","author":"LA Sullivan","year":"2010","unstructured":"Sullivan, L. A. & Brekken, R. A. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2, 165\u2013175 (2010).","journal-title":"MAbs"},{"key":"53433_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat Med 9, 669\u2013676 (2003).","journal-title":"Nat Med"},{"key":"53433_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0074-7696(08)60149-7","volume":"185","author":"G Szebenyi","year":"1999","unstructured":"Szebenyi, G. & Fallon, J. F. Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol 185, 45\u2013106 (1999).","journal-title":"Int Rev Cytol"},{"key":"53433_CR14","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","volume":"19","author":"K Holmes","year":"2007","unstructured":"Holmes, K., Roberts, O. L., Thomas, A. M. & Cross, M. J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19, 2003\u20132012, https:\/\/doi.org\/10.1016\/j.cellsig.2007.05.013 (2007).","journal-title":"Cell Signal"},{"key":"53433_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/0092-8674(94)90032-9","volume":"79","author":"T Spivak-Kroizman","year":"1994","unstructured":"Spivak-Kroizman, T. et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 79, 1015\u20131024 (1994).","journal-title":"Cell"},{"key":"53433_CR16","doi-asserted-by":"publisher","first-page":"10816","DOI":"10.1074\/jbc.274.16.10816","volume":"274","author":"S Gengrinovitch","year":"1999","unstructured":"Gengrinovitch, S. et al. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274, 10816\u201310822 (1999).","journal-title":"J Biol Chem"},{"key":"53433_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1083\/jcb.107.2.743","volume":"107","author":"O Saksela","year":"1988","unstructured":"Saksela, O., Moscatelli, D., Sommer, A. & Rifkin, D. B. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107, 743\u2013751 (1988).","journal-title":"J Cell Biol"},{"key":"53433_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1083\/jcb.110.3.767","volume":"110","author":"O Saksela","year":"1990","unstructured":"Saksela, O. & Rifkin, D. B. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 110, 767\u2013775 (1990).","journal-title":"J Cell Biol"},{"key":"53433_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1432-1033.1994.tb18881.x","volume":"222","author":"A Pineda-Lucena","year":"1994","unstructured":"Pineda-Lucena, A. et al. Effect of low pH and heparin on the structure of acidic fibroblast growth factor. Eur J Biochem 222, 425\u2013431 (1994).","journal-title":"Eur J Biochem"},{"key":"53433_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/jcb.240450208","volume":"45","author":"I Vlodavsky","year":"1991","unstructured":"Vlodavsky, I. et al. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem 45, 167\u2013176 (1991).","journal-title":"J Cell Biochem"},{"key":"53433_CR21","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.1021\/bi00152a026","volume":"31","author":"MA Nugent","year":"1992","unstructured":"Nugent, M. A. & Edelman, E. R. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. Biochemistry 31, 8876\u20138883 (1992).","journal-title":"Biochemistry"},{"key":"53433_CR22","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/S0021-9258(17)41730-3","volume":"269","author":"M Roghani","year":"1994","unstructured":"Roghani, M. et al. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 269, 3976\u20133984 (1994).","journal-title":"J Biol Chem"},{"key":"53433_CR23","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0962-8924(01)02122-5","volume":"11","author":"C Chang","year":"2001","unstructured":"Chang, C. & Werb, Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11, S37\u201343 (2001).","journal-title":"Trends Cell Biol"},{"key":"53433_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0092-8674(00)81768-7","volume":"95","author":"N Hiraoka","year":"1998","unstructured":"Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R. & Weiss, S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365\u2013377 (1998).","journal-title":"Cell"},{"issue":"2","key":"53433_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1055-3207(18)30071-1","volume":"10","author":"William G. Stetler-Stevenson","year":"2001","unstructured":"Stetler-Stevenson, W. G. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 10, 383\u2013392, x. (2001).","journal-title":"Surgical Oncology Clinics of North America"},{"key":"53433_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2796.2003.01297.x","volume":"255","author":"P Carmeliet","year":"2004","unstructured":"Carmeliet, P. Manipulating angiogenesis in medicine. J Intern Med 255, 538\u2013561 (2004).","journal-title":"J Intern Med"},{"key":"53433_CR27","doi-asserted-by":"publisher","first-page":"14313","DOI":"10.1074\/jbc.270.24.14313","volume":"270","author":"SS Apte","year":"1995","unstructured":"Apte, S. S., Olsen, B. & Murphy, G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J. Biol. Chem. 270, 14313\u201314318 (1995).","journal-title":"J. Biol. Chem."},{"key":"53433_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","volume":"92","author":"R Visse","year":"2003","unstructured":"Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92, 827\u2013839 (2003).","journal-title":"Circ Res"},{"key":"53433_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1139\/o96-090","volume":"74","author":"B Anand-Apte","year":"1996","unstructured":"Anand-Apte, B. et al. A Review of Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) and Experimentsl Analysis of its Effect on Primary Tumor Growth. Biochem. and Cell. Biol. 74, 853\u2013862 (1996).","journal-title":"Biochem. and Cell. Biol."},{"key":"53433_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/sj.onc.1209104","volume":"25","author":"W Cruz-Munoz","year":"2006","unstructured":"Cruz-Munoz, W., Kim, I. & Khokha, R. TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene 25, 650\u2013655 (2006).","journal-title":"Oncogene"},{"key":"53433_CR31","first-page":"898","volume":"41","author":"NH Chong","year":"2000","unstructured":"Chong, N. H., Alexander, R. A., Gin, T., Bird, A. C. & Luthert, P. J. TIMP-3, collagen, and elastin immunohistochemistry and histopathology of Sorsby\u2019s fundus dystrophy. Invest Ophthalmol Vis Sci 41, 898\u2013902 (2000).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"53433_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1083\/jcb.148.4.811","volume":"148","author":"ML Fitzgerald","year":"2000","unstructured":"Fitzgerald, M. L., Wang, Z., Park, P. W., Murphy, G. & Bernfield, M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148, 811\u2013824 (2000).","journal-title":"J Cell Biol"},{"key":"53433_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399403006628","volume":"5","author":"MA Lafleur","year":"2003","unstructured":"Lafleur, M. A., Handsley, M. M. & Edwards, D. R. Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5, 1\u201339 (2003).","journal-title":"Expert Rev Mol Med"},{"key":"53433_CR34","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1172\/JCI1584","volume":"101","author":"AH Baker","year":"1998","unstructured":"Baker, A. H., Zaltsman, A. B., George, S. J. & Newby, A. C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101, 1478\u20131487 (1998).","journal-title":"TIMP-3 promotes apoptosis. J Clin Invest"},{"key":"53433_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/bjo.86.1.97","volume":"86","author":"MA Majid","year":"2002","unstructured":"Majid, M. A., Smith, V. A., Easty, D. L., Baker, A. H. & Newby, A. C. Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells. Br J Ophthalmol 86, 97\u2013101 (2002).","journal-title":"Br J Ophthalmol"},{"key":"53433_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nm846","volume":"9","author":"JH Qi","year":"2003","unstructured":"Qi, J. H. et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9, 407\u2013415 (2003).","journal-title":"Nat Med"},{"key":"53433_CR37","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.ophtha.2015.04.035","volume":"122","author":"M Gliem","year":"2015","unstructured":"Gliem, M. et al. Reticular Pseudodrusen in Sorsby Fundus Dystrophy. Ophthalmology 122, 1555\u20131562, https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.035 (2015).","journal-title":"Ophthalmology"},{"key":"53433_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-1-4614-0631-0_34","volume":"723","author":"H Stohr","year":"2012","unstructured":"Stohr, H. & Anand-Apte, B. A review and update on the molecular basis of pathogenesis of Sorsby fundus dystrophy. Adv Exp Med Biol 723, 261\u2013267, https:\/\/doi.org\/10.1007\/978-1-4614-0631-0_34 (2012).","journal-title":"Adv Exp Med Biol"},{"key":"53433_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1350-9462(00)00023-9","volume":"20","author":"JR Evans","year":"2001","unstructured":"Evans, J. R. Risk factors for age-related macular degeneration. Prog Retin Eye Res 20, 227\u2013253 (2001).","journal-title":"Prog Retin Eye Res"},{"key":"53433_CR40","doi-asserted-by":"crossref","unstructured":"Kamei, M., Apte, S. S., Rayborn, M. E., Lewis, H. & Hollyfield, J. G. In Degenerative Diseases of the Retina (eds Luvail, M. M., Anderson, R. E. & Hollyfield, J. G.) 11\u201315 (Plenum Press, 1997).","DOI":"10.1007\/978-1-4615-5933-7_2"},{"key":"53433_CR41","first-page":"p2367","volume":"40","author":"M Kamei","year":"1999","unstructured":"Kamei, M. & Hollyfield, J. TIMP-3 in Bruch\u2019s membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 40, p2367\u20132375 (1999).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"53433_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0161-6420(92)31871-8","volume":"99","author":"R Klein","year":"1992","unstructured":"Klein, R., Klein, B. E. & Linton, K. L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99, 933\u2013943 (1992).","journal-title":"Ophthalmology"},{"key":"53433_CR43","doi-asserted-by":"crossref","unstructured":"Sorsby, A. & Joll Mason, M. E. A fundus dystrophy with unusual features. British journal of Ophthalmology, 67\u201397 (1949).","DOI":"10.1136\/bjo.33.2.67"},{"key":"53433_CR44","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1167\/iovs.10-5899","volume":"52","author":"Q Ebrahem","year":"2011","unstructured":"Ebrahem, Q. et al. Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3. Invest Ophthalmol Vis Sci 52, 6117\u20136123, https:\/\/doi.org\/10.1167\/iovs.10-5899 (2011).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"53433_CR45","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.preteyeres.2003.08.001","volume":"22","author":"A Das","year":"2003","unstructured":"Das, A. & McGuire, P. G. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22, 721\u2013748 (2003).","journal-title":"Prog Retin Eye Res"},{"key":"53433_CR46","doi-asserted-by":"publisher","first-page":"16778","DOI":"10.1074\/jbc.273.27.16778","volume":"273","author":"KP Langton","year":"1998","unstructured":"Langton, K. P., Barker, M. D. & McKie, N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby\u2019s fundus dystrophy mutation. J Biol Chem 273, 16778\u201316781 (1998).","journal-title":"J Biol Chem"},{"key":"53433_CR47","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1093\/hmg\/ddi385","volume":"14","author":"KP Langton","year":"2005","unstructured":"Langton, K. P., McKie, N., Smith, B. M., Brown, N. J. & Barker, M. D. Sorsby\u2019s fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells. Hum Mol Genet 14, 3579\u20133586 (2005).","journal-title":"Hum Mol Genet"},{"key":"53433_CR48","doi-asserted-by":"publisher","first-page":"19927","DOI":"10.1074\/jbc.M109.013763","volume":"284","author":"JH Qi","year":"2009","unstructured":"Qi, J. H. et al. S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis. J Biol Chem 284, 19927\u201319936 (2009).","journal-title":"J Biol Chem"},{"key":"53433_CR49","first-page":"30","volume":"30","author":"JH Qi","year":"2002","unstructured":"Qi, J. H. et al. Expression of Sorsby\u2019s fundus dystrophy mutations in human retinal pigment Epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis. J Biol Chem 30, 30 (2002).","journal-title":"J Biol Chem"},{"key":"53433_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jcp.10361","volume":"197","author":"G Soboleva","year":"2003","unstructured":"Soboleva, G., Geis, B., Schrewe, H. & Weber, B. H. Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. J Cell Physiol 197, 149\u2013156 (2003).","journal-title":"J Cell Physiol"},{"key":"53433_CR51","first-page":"2732","volume":"43","author":"BH Weber","year":"2002","unstructured":"Weber, B. H. et al. A mouse model for Sorsby fundus dystrophy. Invest Ophthalmol Vis Sci 43, 2732\u20132740 (2002).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"53433_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/02713689408995776","volume":"13","author":"G Soubrane","year":"1994","unstructured":"Soubrane, G. et al. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr Eye Res 13, 183\u2013195 (1994).","journal-title":"Curr Eye Res"},{"key":"53433_CR53","doi-asserted-by":"publisher","first-page":"E8214","DOI":"10.1073\/pnas.1710430114","volume":"114","author":"CA Galloway","year":"2017","unstructured":"Galloway, C. A. et al. Drusen in patient-derived hiPSC-RPE models of macular dystrophies. Proc Natl Acad Sci USA 114, E8214\u2013e8223, https:\/\/doi.org\/10.1073\/pnas.1710430114 (2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"53433_CR54","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ejca.2008.06.031","volume":"44","author":"LJ Hawinkels","year":"2008","unstructured":"Hawinkels, L. J. et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44, 1904\u20131913, https:\/\/doi.org\/10.1016\/j.ejca.2008.06.031 (2008).","journal-title":"Eur J Cancer"},{"key":"53433_CR55","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0070-2153(08)60089-7","volume":"24","author":"LM Matrisian","year":"1990","unstructured":"Matrisian, L. M. & Hogan, B. L. Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr Top Dev Biol 24, 219\u2013259 (1990).","journal-title":"Curr Top Dev Biol"},{"key":"53433_CR56","doi-asserted-by":"publisher","first-page":"e11860","DOI":"10.1371\/journal.pone.0011860","volume":"5","author":"P Vempati","year":"2010","unstructured":"Vempati, P., Mac Gabhann, F. & Popel, A. S. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS ONE 5, e11860, https:\/\/doi.org\/10.1371\/journal.pone.0011860 (2010).","journal-title":"PLoS ONE"},{"key":"53433_CR57","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/archopht.123.4.542","volume":"123","author":"IA Barbazetto","year":"2005","unstructured":"Barbazetto, I. A., Hayashi, M., Klais, C. M., Yannuzzi, L. A. & Allikmets, R. A novel TIMP3 mutation associated with Sorsby fundus dystrophy. Arch Ophthalmol 123, 542\u2013543 (2005).","journal-title":"Arch Ophthalmol"},{"key":"53433_CR58","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/jmg.33.3.233","volume":"33","author":"U Felbor","year":"1996","unstructured":"Felbor, U. et al. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby\u2019s fundus dystrophy. J Med Genet 33, 233\u2013236 (1996).","journal-title":"J Med Genet"},{"key":"53433_CR59","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/hmg\/4.12.2415","volume":"4","author":"U Felbor","year":"1995","unstructured":"Felbor, U., Stohr, H., Amann, T., Schonherr, U. & Weber, B. H. A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby\u2019s fundus dystrophy with unusual clinical features. Hum Mol Genet 4, 2415\u20132416 (1995).","journal-title":"Hum Mol Genet"},{"key":"53433_CR60","first-page":"57","volume":"60","author":"U Felbor","year":"1997","unstructured":"Felbor, U., Suvanto, E. A., Forsius, H. R., Eriksson, A. W. & Weber, B. H. Autosomal recessive Sorsby fundus dystrophy revisited: molecular evidence for dominant inheritance. Am J Hum Genet 60, 57\u201362 (1997).","journal-title":"Am J Hum Genet"},{"key":"53433_CR61","doi-asserted-by":"publisher","first-page":"p16778","DOI":"10.1074\/jbc.273.27.16778","volume":"273","author":"K Langton","year":"1998","unstructured":"Langton, K., Barker, M. & McKie, N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby\u2019s fundus dystrophy mutation. J Biol Chem 273, p16778\u201316781 (1998).","journal-title":"J Biol Chem"},{"key":"53433_CR62","doi-asserted-by":"crossref","first-page":"27027","DOI":"10.1016\/S0021-9258(19)61475-4","volume":"275","author":"KP Langton","year":"2000","unstructured":"Langton, K. P. et al. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby\u2019s fundus dystrophy. J Biol Chem 275, 27027\u201327031 (2000).","journal-title":"J Biol Chem"},{"key":"53433_CR63","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ajo.2006.06.003","volume":"142","author":"RJ Lin","year":"2006","unstructured":"Lin, R. J., Blumenkranz, M. S., Binkley, J., Wu, K. & Vollrath, D. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Am J Ophthalmol 142, 839\u2013848 (2006).","journal-title":"Am J Ophthalmol"},{"key":"53433_CR64","first-page":"179","volume":"103","author":"Y Tabata","year":"1998","unstructured":"Tabata, Y., Isashiki, Y., Kamimura, K., Nakao, K. & Ohba, N. A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby\u2019s fundus dystrophy with unusual clinical features. Hum Genet 103, 179\u2013182 (1998).","journal-title":"Hum Genet"},{"key":"53433_CR65","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng1294-352","volume":"8","author":"BH Weber","year":"1994","unstructured":"Weber, B. H., Vogt, G., Pruett, R. C., Stohr, H. & Felbor, U. Mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) in patients with Sorsby\u2019s fundus dystrophy. Nature Genetics 8, 352\u2013356 (1994).","journal-title":"Nature Genetics"},{"key":"53433_CR66","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0161-6420(89)32654-6","volume":"96","author":"PJ Polkinghorne","year":"1989","unstructured":"Polkinghorne, P. J. et al. Sorsby\u2019s fundus dystrophy. A clinical study. Ophthalmology 96, 1763\u20131768 (1989).","journal-title":"Ophthalmology"},{"key":"53433_CR67","first-page":"817","volume":"38","author":"B Anand-Apte","year":"1997","unstructured":"Anand-Apte, B. et al. Inhibition of Angiogenesis by Tissue Inhibitor of Metalloproteinase-3. Invest. Ophthal. Vis. Sci. 38, 817\u2013823 (1997).","journal-title":"Invest. Ophthal. Vis. Sci."},{"key":"53433_CR68","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1172\/jci44762","volume":"121","author":"M Murakami","year":"2011","unstructured":"Murakami, M. et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest 121, 2668\u20132678, https:\/\/doi.org\/10.1172\/jci44762 (2011).","journal-title":"J Clin Invest"},{"key":"53433_CR69","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nm0698-691","volume":"4","author":"M Kato","year":"1998","unstructured":"Kato, M. et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4, 691\u2013697 (1998).","journal-title":"Nat Med"},{"key":"53433_CR70","doi-asserted-by":"publisher","first-page":"91R","DOI":"10.1093\/glycob\/11.6.91R","volume":"11","author":"KJ Bame","year":"2001","unstructured":"Bame, K. J. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 11, 91R\u201398R (2001).","journal-title":"Glycobiology"},{"key":"53433_CR71","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.matbio.2008.01.008","volume":"27","author":"M Fogarasi","year":"2008","unstructured":"Fogarasi, M., Janssen, A., Weber, B. H. & Stohr, H. Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy. Matrix Biol 27, 381\u2013392 (2008).","journal-title":"Matrix Biol"},{"key":"53433_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399405010045","volume":"7","author":"Z Li","year":"2005","unstructured":"Li, Z., Clarke, M. P., Barker, M. D. & McKie, N. TIMP3 mutation in Sorsby\u2019s fundus dystrophy: molecular insights. Expert Rev Mol Med 7, 1\u201315 (2005).","journal-title":"Expert Rev Mol Med"},{"key":"53433_CR73","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche, L. G. et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 48, 134\u2013143 (2016).","journal-title":"Nat Genet"},{"key":"53433_CR74","doi-asserted-by":"publisher","first-page":"e55667","DOI":"10.1371\/journal.pone.0055667","volume":"8","author":"JH Qi","year":"2013","unstructured":"Qi, J. H. et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice. PLoS ONE 8, e55667, https:\/\/doi.org\/10.1371\/journal.pone.0055667 (2013).","journal-title":"PLoS ONE"},{"key":"53433_CR75","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1167\/iovs.06-0732","volume":"48","author":"OP Kocaoglu","year":"2007","unstructured":"Kocaoglu, O. P. et al. Simultaneous fundus imaging and optical coherence tomography of the mouse retina. Invest Ophthalmol Vis Sci 48, 1283\u20131289 (2007).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"53433_CR76","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/jop.2015.0049","volume":"31","author":"RS Sulaiman","year":"2015","unstructured":"Sulaiman, R. S. et al. A Simple Optical Coherence Tomography Quantification Method for Choroidal Neovascularization. J Ocul Pharmacol Ther 31, 447\u2013454 (2015).","journal-title":"J Ocul Pharmacol Ther"},{"issue":"Pt 4","key":"53433_CR77","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1242\/jcs.113.4.643","volume":"113","author":"MJ Cross","year":"2000","unstructured":"Cross, M. J. et al. Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells. J Cell Sci 113(Pt 4), 643\u2013651 (2000).","journal-title":"J Cell Sci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53433-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:19:51Z","timestamp":1671293991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53433-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53433"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53433-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"18 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17429"}}